Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (6829)	7/29/1998 1:12:00 AM
From: Bluegreen	Respond to of 17367

Meanwhile back at St.Elsewhere it is a busy night in the ER. In this fiction piece we have Neuprex just being approved for Meningo. It is in stock and you are up to date on Neuprex's possible uses besides Meningo. The following cases bombard you in rapid succession and the question is whether or not to initiate Neuprex in any or all of the cases along with any other appropriate therapy you deem necessary. Good luck. Case 1 A 25-year-old woman, previously in good health, developed fever, chills, arthralgias, and a fine macular rash over her lower extremities. The following day the rash progressed over her trunk and upper extremities, and became purpuric. The patient developed severe headache and weakness. She was brought to the hospital by ambulance. The patient lived in Minneapolis and had not traveled outside the state in recent months. She had no pets or exposure to animals or ticks. She did not use alcohol, tobacco, or illicit drugs. Her last menstrual period was two weeks earlier. She took no medications regularly, and had no known allergies. On examination her temperature was 101.7 degrees F and her blood pressure was 70/50 with a pulse of 140 beats per minute and respirations of 24 per minute. Mental status was clear. There was no meningismus. There was a diffuse purpuric rash over her body. There was no evidence of abdominal surgery. The rest of the physical exam was unremarkable. Initial laboratory findings included Hb 12.3, WBC 2.5 (65% PMN, 25% bands), platelet count 64,000, Na 135, K 3.4, Cl 103, CO2 10, ABG (4L O2), pH 7.38, pO2 140, pCO2 24. Urine could not be obtained for analysis. Case 2 A 22-year-old male noted pain in his left knee after playing a game of basketball. He took some ibuprofen that night but the pain progressively worsened. The next morning the knee was swollen and red, and the patient had a temperature of 102 degrees F. He went to see his family physician for further evaluation. The patient was otherwise healthy, took no chronic medications, and had no known allergies. On examination, he had a temperature of 101.8 degrees F and otherwise normal vital signs. The left knee was swollen, red, and tender. There was marked tenderness in the knee with weight-bearing or range of motion. Case 3 A 43-year-old man had facial pain and purulent nasal discharge for several days. On the day of admission to the hospital he left work early because of a severe headache. When his wife came home in the evening, she found him in bed, lethargic and feverish. He was brought to the hospital by ambulance and admitted to the intensive case unit. On admission his temperature was 103 degrees F, and blood pressure was 100/60. He responded only to administration of a painful stimulus. He had no rash. There was no evidence of head trauma or recent surgical procedures. No papilledema was seen on fundoscopic examination. Heart, lung, and abdominal exam were unremarkable. No focal neurological deficits were detected. Case 4 A 56-year-old man was hospitalized with a two-day history of high fevers to greater than 102 degrees F and diffuse superficial back pain. Prior to the onset of fever, he had no acute illness and had no history of chronic medical problems except for mild hypertension. On the day of admission he was also noted by his wife to have periods of confusion and difficulty speaking. On admission, his temperature was 101 degrees F. Heart, lung, and abdomen exam were undreadable, and his neck was supple. There were no focal neurologic deficits. Admission labs showed a WBC count of 15,000 with 30% bands. CXR and EKG were normal. In the next six hours, the patience developed hemorrhagic skin lesions on his abdomen and extremities. He became blind in both eyes and was noted to have a loud systolic murmur.

To: Cacaito who wrote (6829)	7/29/1998 7:10:00 AM
From: Robert K.	Respond to of 17367

I used to be reluctant to discuss patents.....But no more.................>> >Pat. No.Title1.5,783,561 Anti-gram-positive bacterial methods and materials 2.5,770,561 Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products 3.5,763,567 Biologically active peptides from funcional domains of bactericidal/permeability-increasing protein and uses thereof 4.5,756,464 Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma 5.5,753,620 Human therapeutic uses of BPI protein products 6.5,741,779 Antithrombotic materials and methods 7.5,733,872 Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof 8.5,703,038 Therapeutic uses of bactericidal-permeability-increasing protein dimer products 9.5,696,090 Pharmaceutical composition 10.5,686,414 Methods of treating conditions associated with corneal transplantation 11.5,674,834 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same 12.5,652,332 Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof 13.5,646,114 Anti-protozoan methods 14.5,643,570 BPI-immunoglobulin fusion proteins 15.5,639,727 Therapeutic uses of bactericidal/permeability increasing protein products 16.5,627,153 Anti-fungal methods and materials 17.5,578,572 Anti-gram-positive bacterial methods and materials 18.5,578,568 Method of treating conditions associated with intestinal ischemia/reperfusion 19.5,523,288 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic 20.5,494,896 Method of treating conditions associated with burn injuries 21.5,488,034 Pharmaceutical composition comprising BPI proteins 22.5,484,705 Method for quantifying lipopolysaccharide binding protein 23.5,466,581 Method for quantifying BPI in body fluids 24.5,466,580 Method for quantifying BPI in body fluids 25.5,447,913 Therapeutic uses of bactericidal/permeability-increasing protein dimer products 26.5,420,019 Stable bactericidal/permeability-increasing protein muteins 27.5,348,942 Therapeutic uses of bactericidal/permeability increasing protein products